Skip to main content

iwCLL 2025 Main banner

iwCLL X / Twitter

159 Views

Poster

1908 - Number Needed to Treat Analyses of Zanubrutinib vs Acalabrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia

Primary Author / Presenter(s)

Mazyar Shadman, MD, MPH

Professor
Fred Hutchinson Cancer Center
Seattle, Washington, United States

Co-Author(s)

DC

David Campbell, PharmD, MS

Curta Inc.
Seattle, Washington, United States
MX

Mei Xue, MBA

BeOne Medicines Ltd., USA
San Carlos, California, United States
MM

Marjan Massoudi, PharmD

BeOne Medicines Ltd
San Carlos, California, United States
KY

Keri Yang, PhD

BeOne Medicines Ltd., USA
San Carlos, California, United States
RW

Rhys Williams, PhD

BeOne Medicines Ltd
San Carlos, California, United States
AC

Asher A. Chanan-Khan, MD

Department of Cancer Biology, Mayo Clinic and Mayo Clinic Cancer Center at St. Vincent’s Medical Center Riverside
Jacksonville, Florida, United States